BidaskClub downgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a hold rating to a sell rating in a research note released on Saturday.
Other analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a buy rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. B. Riley initiated coverage on shares of Arbutus Biopharma in a research report on Friday, January 5th. They set a buy rating and a $10.00 price target for the company. Zacks Investment Research raised shares of Arbutus Biopharma from a sell rating to a hold rating in a research report on Tuesday, November 7th. Leerink Swann reissued a market perform rating and issued a $5.00 price objective (up from $4.00) on shares of Arbutus Biopharma in a research report on Tuesday, November 7th. Finally, ValuEngine cut shares of Arbutus Biopharma from a hold rating to a sell rating in a research report on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $12.50.
Shares of Arbutus Biopharma (NASDAQ:ABUS) opened at $5.25 on Friday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 12-month low of $2.55 and a 12-month high of $8.25. The firm has a market cap of $294.53, a price-to-earnings ratio of -1.05 and a beta of 1.12.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.